Kent u de chatbox al? chat met andere beleggers


Arrowhead Pharmaceuticals (ARWR)

Beleggen in aandelen beurs New York, Dow Jones, Nasdaq-100 en S&P500

maartenverhoeve
Forum veteraan
Forum veteraan
Berichten: 1408
Lid geworden op: 02 jan 2012 21:42
waarderingen: 278
Contacteer:

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door maartenverhoeve »

Ondertussen hebben we een indrukwekkende week achter de rug. Bij een rode Dow stijgen we dagdagelijks door. Ook hoger volume op groene dagen. Ik verwacht eerstdaags een PB. Resultaten of partnership, een vd 2.
In port; Enwave, Ageas, Western Cop, Retail estate, RDS, kbca, roularta, Tessenderlo.,oci, Forfarmers, American airlines en veel arrowhead pharma....





Volg Beursig.com op Twitter en Facebook

     


maartenverhoeve
Forum veteraan
Forum veteraan
Berichten: 1408
Lid geworden op: 02 jan 2012 21:42
waarderingen: 278
Contacteer:

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door maartenverhoeve »

Bijna 10 %erbij vandaag en een mooie uitbraak. Eind juli zitten we weer aan de 60 usd. 16/7 cc, ik ben benieuwd. GLTA.
Stofke liked last!
In port; Enwave, Ageas, Western Cop, Retail estate, RDS, kbca, roularta, Tessenderlo.,oci, Forfarmers, American airlines en veel arrowhead pharma....

Stofke
Premiummember
Premiummember
Berichten: 995
Lid geworden op: 13 okt 2017 16:18
waarderingen: 576
Contacteer:

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door Stofke »

maartenverhoeve schreef:
13 jul 2020 20:07
Bijna 10 %erbij vandaag en een mooie uitbraak. Eind juli zitten we weer aan de 60 usd. 16/7 cc, ik ben benieuwd. GLTA.
Nog een weekje te gaan voor je 60 dollar ;)

Gebruikersavatar
Wimpie85
Premiummember
Premiummember
Berichten: 2684
Lid geworden op: 19 jan 2013 13:48
waarderingen: 1143
Contacteer:

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door Wimpie85 »

maartenverhoeve schreef:
13 jul 2020 20:07
Bijna 10 %erbij vandaag en een mooie uitbraak. Eind juli zitten we weer aan de 60 usd. 16/7 cc, ik ben benieuwd. GLTA.
Waarom staat het niet mee in je onderschrift dan? :think:

Stofke
Premiummember
Premiummember
Berichten: 995
Lid geworden op: 13 okt 2017 16:18
waarderingen: 576
Contacteer:

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door Stofke »

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on June 18, 2020, the Compensation Committee of the Board of Directors approved "inducement" grants to 25 new employees under Rule 5635(c)(4) of the NASDAQ Marketplace Rules. The option grants entitle the employees, in aggregate, to purchase up to 94,000 shares of common stock and receive up to 213,000 restricted stock units. The strike price of the options is set at an exercise price per share of $36.72, the last reported closing price of the Company's common stock on June 18, 2020, the date of grant, except for certain shares which will be priced at the last reported closing price of the Company’s common stock on the date of hire of 11 new employees, anticipated to be within two months of the date of the approval. The grants are outside of the Company's stockholder-approved equity incentive plans. The options vest and become exercisable over a period of four years. The RSUs vest annually over either one to four years.

Stofke
Premiummember
Premiummember
Berichten: 995
Lid geworden op: 13 okt 2017 16:18
waarderingen: 576
Contacteer:

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door Stofke »

1ste pakketje binnen op 48,25

Stofke
Premiummember
Premiummember
Berichten: 995
Lid geworden op: 13 okt 2017 16:18
waarderingen: 576
Contacteer:

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door Stofke »

Arrowhead Pharmaceuticals Hosts Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis

Jul 28, 2020 at 11:59 AM EDT
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 28, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is hosting a key opinion leader webinar today at 12:00 PM EDT on ARO-ENaC, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with cystic
PDF Version
PASADENA, Calif.--(BUSINESS WIRE)--Jul. 28, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is hosting a key opinion leader webinar today at 12:00 PM EDT on ARO-ENaC, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with cystic fibrosis (CF).

The webinar features a presentation by Marcus Mall, M.D., professor and director of the Department of Pediatric Pulmonology and Immunology at The Charité University Medical Center Berlin, who will discuss the current treatment landscape and unmet medical need in treating patients with CF. Arrowhead management is providing a review of the ARO-ENaC program, which utilizes Arrowhead’s proprietary Targeted RNAi Molecule (TRiM™) platform and is the company’s first inhaled RNAi candidate to target pulmonary epithelium. The live webinar and replay may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

Key points discussed on the webinar include the following:

Marcus Mall, M.D., professor and director of the Department of Pediatric Pulmonology and Immunology at The Charité University Medical Center Berlin

The epithelial sodium channel (ENaC) plays an important role in the pathophysiology of CF lung disease and represents a promising alternative target to improve airway surface hydration and mucus clearance in patients, independent of their CFTR genotype
A substantial number of CF patients (without F508del allele) cannot be treated with current CFTR modulators and could benefit from ENaC inhibition
Partial rescue of CFTR with current CFTR modulators does not prevent progression of CF lung disease, resulting in an unmet medical need for further improvement of targeted CF therapy
ENaC inhibition has potential to act synergistically with CFTR modulators by improving the driving force for chloride/fluid secretion mediated by mutant CFTR rescued by CFTR modulators
ENaC inhibition has potential as a novel therapeutic approach to improve mucus clearance and provide clinical benefits to patients with other muco-obstructive lung diseases, including COPD
Erik Bush, Ph.D., vice president, biology, Arrowhead Pharmaceuticals

ENaC is a well-validated therapeutic target for cystic fibrosis and muco-obstructive lung disease
ARO-ENaC overcomes critical limitations of small molecule inhibitors
ARO-ENaC inhalation silences ENaC expression selectively in the lung, doubling mucociliary clearance for weeks post-dose and preserving clearance in a sheep disease model of mucostasis with no evidence of systemic activity (e.g. electrolyte imbalance)
Promising results observed in various preclinical toxicology studies
Javier San Martin, M.D., chief medical officer, Arrowhead Pharmaceuticals

AROENaC1001, a Phase 1/2 study in up to 24 normal healthy volunteers (NHVs) and up to 30 CF patients, is expected to begin dosing in August 2020
Potential Phase 1/2 readout in the first half of 2021 may include safety in NHVs and patients, and an assessment of lung function in patients measured by forced expiratory volume (FEV1) and lung clearance index (LCI)
There is a significant and growing population of patients without adequate response to current CF treatment
Arrowhead is exploring potential accelerated regulatory pathways for patients with the highest unmet need, including Class I patients and other patient subsets with insufficient response to standard of care
CF is a rare disease caused by genetic mutations in the CFTR gene that lead to progressive deterioration in lung function due to poor clearance of mucus and associated recurrent infections. ARO-ENaC is designed to reduce activity of the epithelial sodium channel alpha subunit in the airways of the lung. In patients with CF, CFTR dysfunction causes increased ENaC activity, which contributes to airway dehydration and reduced mucociliary transport. This predisposes patients to persistent lung infections, structural damage, and progressive loss of pulmonary function. ENaC has been extensively explored as a potential therapeutic target for CF, but the development of inhaled small molecule ENaC inhibitors has been limited by on-target renal toxicity and short duration of action in the lung.
NewB76 liked last!

Stofke
Premiummember
Premiummember
Berichten: 995
Lid geworden op: 13 okt 2017 16:18
waarderingen: 576
Contacteer:

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door Stofke »

3 “Perfect 10” Stocks to Snap Up Now
Contributor Jul 28, 2020 7:08PM EDT
Wall Street is sending mixed signals. While the S&P 500 is up 45% from its March lows, the market was choppy throughout most of June and July. On top of this, new COVID-19 cases are being reported at an alarming rate and trade tensions between the U.S. and China are flaring. What does all of this mean? The investing game has changed, so new strategies are needed to keep up with the new rules.

TipRanks has a tool that offers more than just an evaluation on a fundamental and technical basis. Providing a more comprehensive stock analysis, the Smart Score pulls together 8 commonly used predictive metrics, and collates all of the data into a single numerical score. This score ranges from 1 to 10, with 10 being assigned to the names most likely to outperform.

Using TipRanks’ database, we pinpointed three stocks that have earned the enviable “Perfect 10” Smart Score. Let’s dig a bit deeper into the details.

Arrowhead Pharmaceuticals (ARWR)

Through its versatile drug discovery and development platform designed using its patented technologies, Arrowhead Pharmaceuticals develops therapies that target intractable diseases by silencing the genes that cause them. Given its impressive development pipeline, some members of the Street believe that it’s time to take another look at this Perfect 10.

Currently, Phase 1 studies of ARO-APOC3 and ARO-ANG3 are fully enrolled, with updates potentially being provided at the European Society of Cardiology in late August, American Heart Association in November and the National Lipid Association meeting in December. Writing for Piper Sandler, five-star analyst Edward Tenthoff has been impressed by ARWR thus far.

Looking at interim Phase 1 multi-dose data on ARO-APOC3, the therapy was able to generate a 95% reduction in TG. Additionally, ARO-ANG3 demonstrated an LDLc reduction of 39-42% in hypercholesterolemia patients on top of background therapy and a TG reduction of 79% in hypertriglyceridemia patients. Not to mention, the safety and tolerability profile was robust.

Weighing in on the implications, Tenthoff stated, “Clean safety and lipid lowering will enable initiation of pivotal trial starts of ARO-APOC3 in Multifactorial Chylomicronemia (MCM) syndrome and a Phase IIb study of ARO-ANG3 in mixed dyslipedemia by 1H:21. Amgen could report Phase I AMG-890 data and start a Phase II study triggering a milestone.”

Even though COVID-19 forced the company to halt the Phase 2/3 SEQUOIA and open-label Phase 2 AROAAT2002 studies of ARO-AAT, both have now been restarted. The AROAAT2002 study is assessing pre- and post- ARO-AAT treatment biopsies to measure histological liver disease activity over two years, with ARWR potentially releasing six-month biopsy data from the first cohort at AASLD. “While histological changes are not expected at this point, observation of reduction in production of pathological misfolded AAT protein would indicate drug activity,” Tenthoff added.

The company also has other ongoing clinical activity including Phase 1 studies for ARO-HSD to treat NASH, ARO-HIF1 in kidney cancer and ARO-ENaC for cystic fibrosis, and thus, the deal is sealed for Tenthoff. In addition to reiterating an Overweight rating, he kept his $80 price target as is. A twelve-month gain of 65% could be in store, should the analyst’s thesis play out in the year ahead. (To watch Tenthoff’s track record, click here)

Judging by the consensus breakdown, other analysts also like what they’re seeing. 5 Buys and a single Hold add up to a Strong Buy consensus rating. Based on the $64.17 average price target, the upside potential comes in at 33%. (See ARWR stock analysis on TipRanks)

Stofke
Premiummember
Premiummember
Berichten: 995
Lid geworden op: 13 okt 2017 16:18
waarderingen: 576
Contacteer:

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door Stofke »

Arrowhead Pharmaceuticals Earns $20 Million Milestone Payment from Amgen for Start of Phase 2 Trial of AMG 890
Jul 29, 2020 at 7:30 AM EDT
PASADENA, Calif. --(BUSINESS WIRE)--Jul. 29, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has earned a $20 million milestone payment from Amgen following the administration of the first dose of AMG 890, formerly referred to as ARO-LPA, in a Phase 2 clinical study.
PASADENA, Calif.--(BUSINESS WIRE)--Jul. 29, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has earned a $20 million milestone payment from Amgen following the administration of the first dose of AMG 890, formerly referred to as ARO-LPA, in a Phase 2 clinical study. The study is evaluating the efficacy, safety, and tolerability of AMG 890 in subjects with elevated levels of lipoprotein (a) (Lp(a)). Emerging research has shown that elevated levels of Lp(a) are strongly associated with cardiovascular disease. AMG 890 is an investigational RNA interference (RNAi) therapeutic designed to lower Lp(a) for the treatment of cardiovascular disease.

Chris Anzalone, Ph.D., president and CEO at Arrowhead said, “Arrowhead’s proprietary Targeted RNAi Molecule (TRiM™) platform has yielded many promising drug candidates, including AMG 890 being developed by Amgen for the treatment of cardiovascular disease. The start of Amgen’s Phase 2 study and the resulting milestone payment to Arrowhead of $20 million represent important steps forward for the AMG 890 program, and support Arrowhead’s strategy of utilizing our platform and expertise in RNAi therapeutics to build a valuable pipeline of both wholly owned and partnered drug candidates. Amgen has extensive expertise in developing and commercializing innovative cardiovascular medicines and we are excited to see the program continue to advance.”

The clinical study (NCT04270760) is a double-blind, randomized, placebo-controlled Phase 2 study to evaluate efficacy, safety, and tolerability of AMG 890 in 240 subjects with elevated Lp(a). The primary outcome measure is the percent change in Lp(a) from baseline to week 36. Secondary outcome measures include the percent change in Lp(a) from baseline to week 48, percent change in low-density lipoprotein cholesterol (LDL-C) from baseline to weeks 36 and 48, percent change in Apolipoprotein(B) (ApoB) from baseline to weeks 36 and 48, maximum observed concentration (Cmax) of AMG 890, and area under the concentration-time curve (AUC).

Under the terms of the agreement with Amgen announced in September 2016, Arrowhead is eligible to receive development, regulatory, and sales milestone payments. Arrowhead is further eligible to receive up to low double-digit royalties for sales of products under the AMG 890 agreement.

Stofke
Premiummember
Premiummember
Berichten: 995
Lid geworden op: 13 okt 2017 16:18
waarderingen: 576
Contacteer:

Re: Arrowhead Pharmaceuticals (ARWR)

Bericht door Stofke »

Chardan Capital Reiterates “Buy” Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Adam MastersJul 31st, 2020
Arrowhead Pharmaceuticals logoArrowhead Pharmaceuticals (NASDAQ:ARWR)‘s stock had its “buy” rating reiterated by Chardan Capital in a research report issued to clients and investors on Wednesday, Stock Target Advisor reports. They currently have a $81.00 price objective on the biotechnology company’s stock. Chardan Capital’s price target indicates a potential upside of 83.59% from the company’s previous close.

Bijgekocht op 43,42

Deelnemen aan het forum + meer functies?

Discussieer met duizenden beleggers, minder
advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen. Registreer binnen 1 minuut!


Plaats reactie